Neuroscience
Cannabinoid
100%
Long-Term Potentiation
87%
Glucocorticoid Receptor
57%
AM251
54%
Emotional Memory
53%
Endocannabinoid
44%
Hippocampus
43%
Cannabinoid Receptor
43%
Amygdala
43%
Endocannabinoid System
41%
Cannabis
39%
Posttraumatic Stress Disorder
39%
Synaptic Plasticity
32%
Basolateral Amygdala
32%
Short-Term Memory
32%
Cannabinoid 1 Receptor
31%
Behavior (Neuroscience)
31%
Cognitive Disorders
30%
CB1 Receptor Antagonists
29%
AM404
23%
Nucleus Accumbens
21%
Prefrontal Cortex
21%
Gray Matter
20%
Receptor Agonists
19%
Receptor Antagonist
16%
URB597
16%
Agonist
12%
Fatty Acid Amidase
12%
Subiculum
10%
Brain Areas
10%
Long-Term Depression
9%
CB2 Receptor Agonist
9%
Learning Disabilities
8%
Anhedonia
8%
Anxiogenic
6%
Anxiety Disorder
6%
Dementia Praecox
5%
Psychosis
5%
Neuroscience
5%
Pharmacology, Toxicology and Pharmaceutical Science
Posttraumatic Stress Disorder
72%
Endocannabinoid System
61%
Cannabinoid
59%
URB597
59%
Disease
43%
Cannabinoid 1 Receptor
39%
Endocannabinoid
39%
Injury
28%
Cannabinoid 1 Receptor Antagonist
17%
Fatty Acid Amidase Inhibitor
17%
AM251
17%
Fatty Acid Amidase
13%
Receptor Agonist
10%
Rat Model
6%
Mouse Model
6%
Cannabis
6%
Anxiety Disorder
6%
Keyphrases
Anxiety-related Disorders
32%
Adolescent Cannabis Use
32%
Psychosis
32%
Brain Structure
32%
Endocannabinoid System
32%
Gray Matter Volume
28%
Posttraumatic Stress Disorder
26%
Cannabinoids
26%
Cannabis
10%
Density Reduction
8%
Cannabis Use
8%
Psychotic Disorders
8%
Schizophrenia
8%
Neurobiology
8%
Ventral Subiculum
8%
Object Recognition Task
8%
Psychotic
8%
Risk Factors
8%
Density Estimates
8%
RU38486
7%
Preclinical Research
6%
Preclinical Data
6%
Clinical Research
6%
Anxiogenic Effect
6%
Untoward Effect
6%
Anxiety-like Behavior
6%
Self-reported Reasons
6%
Emotion Regulation
6%
Dysregulation
6%
Mouse Model
6%
Endocannabinoids
6%
Paradigm Model
6%
Rat Model
6%
Beneficial Outcomes
6%
Clinical Setting
6%
Psychiatric Disorders
6%
Targeted Therapeutics
6%
Anxiety Disorders
6%
